In Norway, the uptake of infliximab biosimilars as of 4th quarter 2018 was 98 percent, and thus the highest among developed countries (OECD). That means that 98 percent of all used units of that drug were biosimilars.
Uptake of infliximab biosimilars in select countries as of 2018, by share of units
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
PMPRB. (May 4, 2020). Uptake of infliximab biosimilars in select countries as of 2018, by share of units [Graph]. In Statista. Retrieved November 19, 2024, from https://www.statista.com/statistics/1119054/uptake-of-infliximab-biosimilars-in-oecd-countries/
PMPRB. "Uptake of infliximab biosimilars in select countries as of 2018, by share of units." Chart. May 4, 2020. Statista. Accessed November 19, 2024. https://www.statista.com/statistics/1119054/uptake-of-infliximab-biosimilars-in-oecd-countries/
PMPRB. (2020). Uptake of infliximab biosimilars in select countries as of 2018, by share of units. Statista. Statista Inc.. Accessed: November 19, 2024. https://www.statista.com/statistics/1119054/uptake-of-infliximab-biosimilars-in-oecd-countries/
PMPRB. "Uptake of Infliximab Biosimilars in Select Countries as of 2018, by Share of Units." Statista, Statista Inc., 4 May 2020, https://www.statista.com/statistics/1119054/uptake-of-infliximab-biosimilars-in-oecd-countries/
PMPRB, Uptake of infliximab biosimilars in select countries as of 2018, by share of units Statista, https://www.statista.com/statistics/1119054/uptake-of-infliximab-biosimilars-in-oecd-countries/ (last visited November 19, 2024)
Uptake of infliximab biosimilars in select countries as of 2018, by share of units [Graph], PMPRB, May 4, 2020. [Online]. Available: https://www.statista.com/statistics/1119054/uptake-of-infliximab-biosimilars-in-oecd-countries/
